Aspect Biosystems
Aspect Biosystems develops bioprinted tissue therapeutics using AI-powered bioprinting technology, computational design tools, advanced biomaterials, and therapeutic cells.
- CEO / Founder
- Tamer Mohamed
- Team Size
- 51-200
- Stage
- Active
- Total Funding
- $290M
- Latest Round
- Government Investment - $79M - April 2026
- Key Investors
- Dimension; Novo Nordisk; Radical Ventures; Pallasite Ventures; Pangaea Ventures; Rhino Ventures; T1D Fund; InBC Investment Corp.; Endure Capital; Relentless Pursuit Partners
Technology & Products
Key Products
Aspect Biosystems develops bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions for metabolic and endocrine diseases. Their platform integrates bioprinting, computational design, therapeutic cells, and biomaterials.
Technological Advantage
Full-stack tissue therapeutic platform combining tissue engineering, cell therapy, biomaterials, computer vision, and robotics.
Differentiation
Value Proposition
Creating a new category of cellular medicines offering functional cures for metabolic and endocrine diseases.
How They Differentiate
Differentiates through an integrated AI-powered bioprinting platform that combines multiple advanced technologies, setting it apart from traditional tissue engineering approaches.
Market & Competition
Target Customers
Patients suffering from serious metabolic and endocrine ailments.
Industry Verticals
["Regenerative medicine","Tissue engineering","Cellular therapies"]
Competitors
Organovo; Cyfuse Biomedical; Other biotech firms in cellular therapies and biomaterials
Growth & Milestones
Growth Metrics
Advancing projects toward clinical trials and secured a C$200m collaboration with the Canadian and British Columbian governments.
Major Milestones
["Secured $115 million in Series B funding","Advancing multiple projects toward clinical trials","C$200m collaboration with Canadian and British Columbian governments"]
Notable Customers
Novo Nordisk